Financing

Eveliqure has been successful in raising private investment and significant public funding to support its research and development activities.

shigetecvax_logo.png

Eveliqure has been an awarded an FFG Basis Grant for €2.6M from the Austrian Research Promotion Agency, and €190k from the Austria Wirtschaftsservice.

Eveliqure has been awarded a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC, through Phase 2 clinical testing. NIAID has made a base award of $215,093 with a total contract value of $20.6 million.

Eveliqure is part of the SHIGETECVAX consortium of world-leading vaccine organizations (The European Vaccine Initiative (consortium leader), Eveliqure Biotechnologies, University of Gothenburg, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) and PATH) who have received an €8.6M grant over 5 years for the manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity of the ShigETEC vaccine studies in two different populations, adults in Europe and in both adults and children in Bangladesh. The award is funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568. ...Read more

Eveliqure has also received financing from a number of private individuals, venture firms and partners including Arax Capital Partners.

Headquarters

Eveliqure Biotechnologies GmbH

Campus Vienna Biocenter


Karl-Farkas-Gasse 22

A-1030 Vienna

Austria

  • White Facebook Icon
  • White LinkedIn Icon

© 2019 Eveliqure Biotechnologies GmbH